| Sheila Zeilman, CRNA | |
|
509 N Broad St, Underwood Memorial Hospital 3rd Floor, Woodbury, NJ 08096 | |
| (856) 845-0100 | |
| (856) 853-9334 |
| Full Name | Sheila Zeilman |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 26 Years |
| Location | 509 N Broad St, Woodbury, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104895937 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 26NJ00265500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Inspira Medical Center Elmer | Elmer, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Jersey Anesthesia And Pain Physicians Pc | 0840181152 | 35 |
News Archive
Angiotension-converting enzyme (ACE) inhibitors, medications commonly used to treat hypertension (high blood pressure), may reduce cardiovascular risk and the risk of death in patients with coronary artery disease, according to a new analysis of previously conducted clinical trials reported in the Archives of Internal Medicine.
Synta Pharmaceuticals Corp. today announced that preclinical results presented at the "Bridging the Gap 2010" Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms' tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.
When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients that ultimately take the drugs, raising questions about the direct applicability of trial data.
The on-going phase II trial on Octapharma's 10% intravenous immunoglobulin octagam®10% will be a topic at the up-coming International Conference on Alzheimer's Disease to take place in Honolulu, Hawaii from July 10 to 15.
A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.
› Verified 6 days ago
| Entity Name | South Jersey Anesthesia And Pain Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700821352 PECOS PAC ID: 0840181152 Enrollment ID: O20040324000439 |
News Archive
Angiotension-converting enzyme (ACE) inhibitors, medications commonly used to treat hypertension (high blood pressure), may reduce cardiovascular risk and the risk of death in patients with coronary artery disease, according to a new analysis of previously conducted clinical trials reported in the Archives of Internal Medicine.
Synta Pharmaceuticals Corp. today announced that preclinical results presented at the "Bridging the Gap 2010" Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms' tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.
When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients that ultimately take the drugs, raising questions about the direct applicability of trial data.
The on-going phase II trial on Octapharma's 10% intravenous immunoglobulin octagam®10% will be a topic at the up-coming International Conference on Alzheimer's Disease to take place in Honolulu, Hawaii from July 10 to 15.
A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sheila Zeilman, CRNA Po Box 390, Scranton, PA 18501 Ph: (570) 346-7797 | Sheila Zeilman, CRNA 509 N Broad St, Underwood Memorial Hospital 3rd Floor, Woodbury, NJ 08096 Ph: (856) 845-0100 |
News Archive
Angiotension-converting enzyme (ACE) inhibitors, medications commonly used to treat hypertension (high blood pressure), may reduce cardiovascular risk and the risk of death in patients with coronary artery disease, according to a new analysis of previously conducted clinical trials reported in the Archives of Internal Medicine.
Synta Pharmaceuticals Corp. today announced that preclinical results presented at the "Bridging the Gap 2010" Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms' tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.
When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients that ultimately take the drugs, raising questions about the direct applicability of trial data.
The on-going phase II trial on Octapharma's 10% intravenous immunoglobulin octagam®10% will be a topic at the up-coming International Conference on Alzheimer's Disease to take place in Honolulu, Hawaii from July 10 to 15.
A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.
› Verified 6 days ago
Lisa Howey, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 509 N Broad St, 3rd Floor Underwood Memorial Hospital, Woodbury, NJ 08096 Phone: 856-845-0100 Fax: 856-853-9334 | |
Lydia Ann Campbell, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 509 N Broad St, 3rd Floor Underwood Memorial Hospital, Woodbury, NJ 08096 Phone: 856-845-0100 Fax: 856-853-9334 | |
Mrs. Christina M Tortella, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 509 N Broad St, 3rd Floor Underwood Memorial Hospital, Woodbury, NJ 08096 Phone: 856-845-0100 Fax: 856-353-9334 | |
Mr. Sanford R. Stark, CRNA, PHD Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 323 S Girard St, Woodbury, NJ 08096 Phone: 856-853-9277 Fax: 856-853-1633 | |
Mrs. Janine M. Dronson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 509 N Broad St, Woodbury, NJ 08096 Phone: 856-845-0100 | |
David Szurek, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 509 N Broad St, Underwood Memorial Hospital 3rd Floor, Woodbury, NJ 08096 Phone: 856-845-0100 Fax: 856-853-9334 |